Abraxis

Life Beyond Cancer Women's Retreat Calls for Applications

...ry resort in Catalina, Ariz., is offered at an extremely affordable cost thanks to many sponsors including Platinum Sponsor Eisai , Gold Sponsors abraxis Oncology and Miraval luxury resort, Silver Sponsor James Lasker, MD , and contributor BAG IT , but space is extremely limited. Deadline fo...

Drug May Extend Life When Breast Cancer Spreads

...gs known as taxanes. The study, which was a phase 2 trial, was funded by abraxis BioScience, which makes Abraxane. The findings are reported in the May 26 i..." Gradishar, who was the lead author for the study, is also a consultant to abraxis BioScience. The chemotherapy drugs docetaxel, marketed as Taxotere, and ...

RAND Launches Unique Tool to Evaluate Health Care Proposals

...s, corporations, corporate foundations, philanthropic foundations, and health system stakeholders. To date, funders include the following: AARP; abraxis BioScience, Patrick Soon-Shiong, MD, Founder, Chairman, and CEO; Aetna Foundation; Alcoa; Amgen Foundation; Blue Cross Blue Shield of Massachusetts; C...

Mayor's Office Declares October 13 as First Metastatic Breast Cancer Awareness Day for New York City

...rvices at Memorial Sloan-Kettering Cancer Center, founded MBCN. MBCN is supported in part through charitable contributions from many sources including abraxis BioScience and AstraZeneca. Conference Information: Date: Saturday, October 13, 2007 Location: NYU Medical Center, 401 East 30 Street, between...

Abraxis in Medical Technology

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, glo...ith bevacizumab as an effective antitumor agent. abraxis continues to explore the role of nab-technology fo... About nab(TM) Technology Platform Developed by abraxis BioScience, nanoparticle albumin-bound (nab(TM)) t...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, glo...ive, head-and-neck cancer patients (25 percent). abraxis continues to explore the role of nab-technology fo... About nab(TM) Technology Platform Developed by abraxis BioScience, nanoparticle albumin-bound (nab(TM)) t...

Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway

... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, glo...e role of mTOR inhibition has led investigators at abraxis to explore the use of the nanoparticle albumin-bou...se I clinical trials with nab-rapamycin in 2007. abraxis continues to explore the role of nab technology fo...

Abraxis in Biological News

2 new therapies show promise for cancer patients

... in pancreatic cancer specimens. The SPARC protein is being investigated by abraxis BioScience in this trial as a potential target for nab-paclitaxel. A test for SPARC, developed at abraxis and Caris MPI and applied by Caris MPI under contract with Abraxis, was uti...

Nanoparticle Breast Cancer Drug Approved by FDA

... be due to preferential delivery of albumin-bound paclitaxel to cancer cells. Abraxane was developed by American Bioscience and will be marketed by abraxis Oncology, a division of American Pharmaceutical Partners. ...

Abraxis in Biological Technology

UCLA welcomes startup to new incubator space at California NanoSystems Institute

...r. Patrick Soon-Shiong, a UCLA visiting professor of bioengineering and of microbiology, immunology and molecular genetics and founder and chairman of abraxis BioScience, a founding partner of the CNSI. ...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

... highly fragmented and is characterized by the presence of several key and niche players. Major market participants in the nanomedicine market include abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmac...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

...ects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine Author(s): Neil Desai, Osmond D'Cruz, Vuong Trieu. abraxis BioScience, LLC., Los Angeles, CA Time/location: 1:00 PM - 5:00 PM, Hall B-F, Poster Section 33, # 9 Abstract Summary: According to Investiga...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... SNTA ) ZYMOGENETICS INC (NASDAQ: ZGEN ) Add abraxis BIOSCIENCE INC (NASDAQ: ABII ) CHUGAI PHARM CO (...EL HOLDING AG-REG (SWX, Switzerland: SPPN) Add abraxis BIOSCIENCE INC (NASDAQ: ABII ) BIOMARIN PHARMACE...NASDAQ: SIAL ) WATERS CORP (NYSE: WAT ) Add abraxis BIOSCIENCE INC NEW (NASDAQ: ABII ) AMERISOURCEBE...

Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium

...asense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid t...

2006: A mixed blessing for Midwest life science companies

... Missouri $77.72 $63.32 +23% $5.2 18. abraxis Bioscience (ABBI) Illinois $27.34 $38.63 ...Laggards - 2006 Company, % Decline 1. abraxis Bioscience, 2. St. Jude Medical, 3. H...w business from a number of hospital groups. abraxis Bioscience suffered, in spite of the successful ...

Midwest life science stocks sizzle in a tepid first quarter

... $6.4 17. Sigma-Aldrich (SIAL) $41.52 $39.21 +6% $5.5 18. abraxis Bioscience (ABBI) $26.71 $27.60 $4.4 19. Dade-Behring (DADE) ... Stock Price Laggards Company - % Change 1. Medtronic, . 2. abraxis Bioscience, . 3. Procter & Gamble, . 4. 3M, . 5. St. Jude Medic...

Midwest life science stocks kept sizzling in Q2

... 17) Sigma-Aldrich (SIAL) $39.21 $41.52 $42.67 +9% $5.6 18) abraxis Bioscience (ABBI) $27.60 $26.71 $22.23 $3.6 19) Dade-Behri...8. Eli Lilly +7% Stock Price Laggards Company % Growth 1. abraxis Bioscience 2. AllScripts Healthcare 3. Walgreen 4. Proct...